NPPA sent back 200 fixed dose combination applications

Recent Articles

• What is the meaning of pharmaceutical profiling?
• What is phase zero study? What it’s significance?
• Sanofi-kymab-deal: Sanofi’s acquisition of a clinical-stage biopharmaceutical company Kymab
• Covishield received emergency use authorization in India
• Glenmark introducing Remogliflozin + Vildagliptin combination first time in India
• Myovant and Pfizer’s $4.2 Billion Deal for Orgovyx
• Insight on Aurobindo and COVAXX exclusive licensing agreement
• Pfizer, BioNTech covid vaccine approval tilldate
• Chugai received MHLW, Japan marketing authorization for humanized anti-PD-L1 monoclonal antibody, Tecentriq to treat unresectable advanced/recurrent NSCLC
• Lynparza received marketing authorization by MHLW, Japan to treat advanced ovarian, prostate and pancreatic cancers
• AstraZeneca – Alexion $39 billion deal
• UK approves Pfizer-BioNTech’s COVID-19 vaccine. Rollout in week time
• Saudi Arabia signs non-binding vaccine agreement with CureVac
• Telix Pharma to acquire TheraPharm GmbH
• Case Study: Clinical basis of MHLW approval of Astellas’s Evrenzo to treat anemia of CKD in adult patients not on dialysis
• Covid 19 Vaccine development and commercialization status | More than 50 vaccine candidate under development
• PostEra codevelopment deal with NeuroLucent for Alzheimer’s disease
• AbbVie, Eisai received new indication approval for Humira to treat pyoderma gangrenosum
• Pfizer submitted application for emergency use of Covid vaccine
• Take Self Competency Test in Esxport Documentation